X4 Pharmaceuticals (XFOR) Accumulated Expenses (2017 - 2025)

X4 Pharmaceuticals' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $18.6 million for Q4 2025.

• Quarterly Accumulated Expenses fell 19.13% year-over-year to $18.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $18.6 million (down 19.13% YoY) and the FY2025 annual result came in at $18.6 million, down 19.13% from the prior year.
• Accumulated Expenses was $18.6 million for Q4 2025 at X4 Pharmaceuticals, up from $16.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $23.0 million in Q4 2024 and bottomed at $6.9 million in Q1 2022.
• A 5-year average of $13.3 million and a median of $12.7 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2021 — Accumulated Expenses soared 85.03% — and 2022, when it slumped 35.76%.
• X4 Pharmaceuticals' Accumulated Expenses stood at $7.9 million in 2021, then soared by 52.91% to $12.0 million in 2022, then gained by 6.5% to $12.8 million in 2023, then jumped by 79.5% to $23.0 million in 2024, then retreated by 19.13% to $18.6 million in 2025.
• Business Quant data shows XFOR's Accumulated Expenses at $18.6 million in Q4 2025, $16.7 million in Q3 2025, and $13.1 million in Q2 2025.